People with HIV/HCV co-infection see good cure rates in real-world practice in Madrid
8-week triple DAA combo cures most people with genotype 1-6 hepatitis C
Birth cohort screening and linkage to care for HCV treatment still weak in United States
AbbVie pangenotypic combination cures 98% or above across genotypes
AbbVie pangenotypic combination cures almost all hard-to-treat people with HCV genotype 3
US Veterans Affairs and Australia show potential for rapid elimination of hepatitis C
Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones
Grazoprevir/elbasvir + sofosbuvir highly effective for hard-to-treat genotype 3 hepatitis C patients
